Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double Blind, Study of Intravenous TD 1792 Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections

NCT00442832 is registered in ClinicalTrials.gov with Theravance Biopharma as lead sponsor.

NCT NCT00442832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00442832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double Blind, Study of Intravenous TD 1792 Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections
Lead sponsor
Theravance Biopharma
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2006
Completion date
May 31, 2007
Enrollment
203 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

staphylococcal skin infection